Journal Article

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

De Luca, Massimo, Ciardiello, Fortunato, Adinolfi, Luigi Elio, Guerrera, Barbara, Sasso, Ferdinando Carlo, Miglioresi, Lucia, Coppola, Nicola, Fasano, Morena, Valente, Giovanna, Berretta, Massimiliano, Rinaldi, Luca, Pafundi, Pia Clara, Morisco, Filomena, Izzi, Antonio, Monari, Caterina, Perrella, Alessandro, Guarino, Maria, Piai, Guido, Martinelli, Erika, Nevola, Riccardo

2019

Overview

Background An unexpected increased HCC recurrence and occurrence rate among HCV patients treated with direct acting antivirals combination has been reported. Aim of the study was the evaluation of early HCC occurrence rate and its risk factors in a HCV infected population, treated with direct-acting-antivirals. Methods According to the Italian ministerial guidelines for direct-acting-antivirals treatment, 1022 consecutive HCV patients treated with direct-acting-antivirals were enrolled. Patients either with active HCC at imaging or history of previous treated HCC, HBV or HIV co-infection, or liver transplant recipients were excluded. The SVR, defined as the persistent absence of detectable serum HCV-RNA 12 weeks after the end of treatment (SVR12), was assessed for all enrolled patients. Abdominal ultrasound was performed before starting antiviral therapy, and repeated every 6 months. HCC was diagnosed according to the international guidelines. Patients showing either nodular patterns suggestive of HCC or with uncertain dynamic vascular behaviour were excluded from a further follow-up. Results Nine hundred and eighty-five patients completed the 48 weeks follow-up after the end of treatment. A Sofosbuvir-based regimen was administered in the 74.9% of patients, among whom, the 71.6% underwent a simultaneous Ribavirin administration. A sustained virological response at 12 weeks off treatment was documented in 966 patients (98.2%). During the post treatment follow-up HCC was detected in 35 patients, with a cumulative incidence rate of the 3.55%. At multivariate analysis, four variables resulted independently associated with HCC development, both in a cirrhosis based and a class B Child based model, respectively: cirrhosis/class B Child, therapeutic schedule including Sofosbuvir without Ribavirin, liver stiffness values, male gender and presence of diabetes. A multivariate analysis performed on Child A cirrhotic patients, showed that Sofosbuvir based therapeutic treatment without Ribavirin had a HCC occurrence 5.7 higher than Ribavirin-based schedules with or without Sofosbuvir (p < 0.0001, OR: 5.686, 95% CI 2.455–13.169). Conclusions Our data suggest that early HCC occurrence appears more frequently related to Sofosbuvir-based therapy without Ribavirin which, indeed, seems to play a protective role on HCC onset. Therefore, a careful follow-up should be mandatory, especially in those regimens including Sofosbuvir without Ribavirin.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Antiviral agents / Antiviral drugs / Biomedical and Life Sciences / Biomedicine / Care and treatment / Cell cycle / Cirrhosis / Complications and side effects / Consent / Diabetes mellitus / Direct acting antivirals / HCC / HCV cirrhosis / Hepatitis B / Hepatitis C / Hepatitis C virus / Hepatocellular carcinoma / HIV / Human immunodeficiency virus / Immune system / Immune-surveillance / Immunovirology / Infection / Infections / Liver / Liver cirrhosis / Liver diseases / Liver transplantation / Medical research / Medicine/Public Health / Multivariate analysis / NMR / Nuclear magnetic resonance / Organ transplant recipients / Organ transplantation / Ribavirin / Ribonucleic acid / Risk factors / RNA / Schedules / Statistics / Testing / Type 2 diabetes / Ultrasonic imaging / Ultrasound